News - Kyowa Hakko Kirin, AstraZeneca

Filter

Popular Filters

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

Back to top